<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00567034</url>
  </required_header>
  <id_info>
    <org_study_id>2006-P-0002381/3</org_study_id>
    <secondary_id>F1D-US-X306</secondary_id>
    <nct_id>NCT00567034</nct_id>
  </id_info>
  <brief_title>Augmenting Zyprexa With Naltrexone to Ameliorate Metabolic Side-Effects</brief_title>
  <acronym>Zyprexa</acronym>
  <official_title>Augmenting Zyprexa With Naltrexone: Normalization of the Weight Gain Side Effect and the CNS Reward and Sensory Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mclean Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mclean Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine whether the opioid antagonist naltrexone is&#xD;
      helpful in ameliorating the weight gain and other adverse metabolic side effects experienced&#xD;
      by schizophrenic patients taking the second generation antipsychotic (SGA) Zyprexa.&#xD;
      Schizophrenics may have an altered/enhanced endogenous opioidergic drive, and because of&#xD;
      this, normally painful stimuli will be sensed as less painful in schizophrenics vs. healthy&#xD;
      controls. A secondary hypothesis for this study is that naltrexone augmentation of Zyprexa&#xD;
      will normalize subjective pain ratings. Our tertiary objective is to examine the safety and&#xD;
      tolerability of naltrexone in Zyprexa-treated patients with schizophrenia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Zyprexa is one of the most commonly prescribed second generation antipsychotic drugs (SGAs),&#xD;
      but its (and other SGA's) side effects contribute to the development of obesity and to the&#xD;
      &quot;Metabolic Syndrome.&quot; Both conditions, which are more prevalent even in unmedicated&#xD;
      schizophrenic patients, are associated with increased cardiovascular morbidity and mortality.&#xD;
      The mechanisms of these side effects are likely to be multifactorial and to involve&#xD;
      peripheral and central factors alike. The present proposal asks a fundamental question: How&#xD;
      the endogenous opioidergic systems are involved in Zyprexa-induced obesity and in related&#xD;
      metabolic disturbances. We further hypothesize that if the excess of central opioid activity&#xD;
      creates metabolic problems for patients, it is reasonable to expect amelioration of the&#xD;
      symptoms through blockade of opioid receptors. The proposed project is designed to test this&#xD;
      hypothesis by complimenting clinical psychopharmacology with pain medicine research and&#xD;
      functional magnetic resonance imaging (fMRI) to empirically measure clinical outcomes of&#xD;
      Zyprexa pharmacotherapy augmentation with the opioid receptor antagonist, naltrexone. Our&#xD;
      objectives and hypotheses are as follows: to determine the effects of naltrexone on weight&#xD;
      gain, metabolic (e.g., cholesterol, lipids, insulin, leptin and glucose levels),&#xD;
      anthropometric and nutritional characteristics in Zyprexa treated schizophrenic patients, to&#xD;
      examine the effects of naltrexone on subjective pain ratings, and to investigate the safety&#xD;
      and tolerability of naltrexone in Zyprexa-treated schizophrenic patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight and Body Mass Index</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective pain ratings, fMRI activations in the a priori selected ROIs, waist, waist/hip ratio, fasting blood glucose, LDL cholesterol, HDL cholesterol, triglycerides, fat body mass, insulin, leptin, and food intake</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Psychotic Disorders</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>taking naltrexone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>taking placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>naltrexone</intervention_name>
    <description>50mg naltrexone, 1 tablet a day for 12 weeks.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>lactose placebo, 1 capsule every day for 12 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meeting DSM-IV-TR criteria for schizophrenia/schizoaffective disorder, confirmed by&#xD;
             clinical interview with PI and SCID-I.&#xD;
&#xD;
          -  On a stable dose of Zyprexa (i.e., greater than or equal to 10mg/day and less than or&#xD;
             equal to 30mg/day) for at least 2 months; patients on typical antipsychotics or in a&#xD;
             medications-free state will be also included and used for baseline comparison.&#xD;
&#xD;
          -  Sufficient clinical stability (i.e., BPRS psychotic symptoms score of less than 19;&#xD;
             BPRS anxiety/depression symptoms score of less than 15).&#xD;
&#xD;
          -  Participation approved by the treating psychiatrist.&#xD;
&#xD;
          -  BMI greater than or equal to 30kg/m^2 or BMI greater than or equal to 27kg/m^2 plus&#xD;
             one symptom of the &quot;Metabolic Syndrome&quot; (i.e., fasting blood sugar greater than&#xD;
             125mg/dL, hypertension or dyslipidemia).&#xD;
&#xD;
          -  Sufficient social stability following study admission, such as having safe, reliable&#xD;
             living quarters, telephone access and at least one living relative or significant&#xD;
             other willing to assist the subject following discharge from the study and to assist&#xD;
             the staff if necessary to locate the subject subsequently.&#xD;
&#xD;
          -  English speaking and reading ability sufficient to comprehend consent without&#xD;
             assistance.&#xD;
&#xD;
          -  Good physical health, no history of significant medical, surgical, or neurological&#xD;
             illness, including any history of head trauma.&#xD;
&#xD;
          -  Right-handedness&#xD;
&#xD;
          -  Able to cooperate and comply with study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  DSM-IV-TR diagnosis of current drug/alcohol dependence.&#xD;
&#xD;
          -  Any lifetime history of dementia, bipolar disorder, major depression, other psychotic&#xD;
             disorder, past or current drug/alcohol dependence, past or current eating disorder.&#xD;
&#xD;
          -  Potentially confounding neurological condition (e.g., seizure disorder, head trauma&#xD;
             accompanied by loss of consciousness greater than ten minutes or amnesia, brain&#xD;
             surgery, multiple sclerosis, Parkinson's disease), or potentially confounding medical&#xD;
             condition (e.g., diabetes mellitus or other endocrinopathy, chronic obstructive&#xD;
             pulmonary disease, congestive heart failure, hepatitis, hepatic failure or cirrhosis,&#xD;
             AIDS, pacemaker, kidney problems, hypokalemia, edema, and allergy to glucose).&#xD;
&#xD;
          -  Allergy or hypersensitivity to naltrexone&#xD;
&#xD;
          -  Abnormal laboratory, ECG or EEG results, elevated serum aminotransferases.&#xD;
&#xD;
          -  Use within the previous month of any potentially confounding medications such as&#xD;
             opioid agonists (e.g., morphine or codeine) or drugs with prominent&#xD;
             orexigenic/anorexigenic effects (e.g., anticholinergics), insulin, oral hypoglycemics,&#xD;
             amphetamines, opioid analgesics, anti-depressants including tricyclics, MAO inhibitors&#xD;
             or mirtazapine, as determined by history and/or urine toxicology screen.&#xD;
&#xD;
          -  Patient is pregnant or planning on becoming pregnant.&#xD;
&#xD;
          -  Any cognitive impairment that precludes informed consent.&#xD;
&#xD;
          -  Any chronic pain condition and/or any condition that may require opioid treatment in&#xD;
             the course of the study.&#xD;
&#xD;
          -  Dangerousness: any suicidal, assaultive or homicidal risks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Igor Elman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mclean Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McLean Hospital</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>December 3, 2007</study_first_submitted>
  <study_first_submitted_qc>December 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2007</study_first_posted>
  <last_update_submitted>October 24, 2013</last_update_submitted>
  <last_update_submitted_qc>October 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mclean Hospital</investigator_affiliation>
    <investigator_full_name>Igor Elman, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Zyprexa</keyword>
  <keyword>naltrexone</keyword>
  <keyword>schizophrenia</keyword>
  <keyword>Metabolic Syndrome</keyword>
  <keyword>pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

